# CellVoyant Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellvoyant-technology

- Industry: Biotechnology
- Headquarters: Bristol, UK
- Website: www.cellvoyant.com
- Total disclosed funding: $9.3M
- Latest round: Seed (Oct 9, 2023)
- Investors on record: 4

## About

Based in Bristol, UK, and founded in 2021 by CEO Rafael E. Carazo Salas, CellVoyant Technology Ltd, a.k.a. CellVoyant is an AI-first biotechnology company that focuses on developing stem cell-based therapies for chronic diseases by leveraging AI-first live cell imaging technology, which helps in predicting and optimizing stem cell differentiation to manufacture any cell and tissue in the body at scale. In December 2023, CellVoyant raised GBP 7.6 million in seed funding led by Octopus Investments, with participation from Horizons Ventures, Air Street Capital, and Verve Ventures.

The company is developing patent-pending platforms called FateView and FateCast, which combine advanced AI with live cell imaging. The platform enables scientists to extract real-time spatial and temporal information from cell mixtures, which allows them to understand cell composition and forecast their behavior with unprecedented precision.

CellVoyant plans to use its proceeds from December 2023 funding to accelerate its research and development capabilities, specifically through increasing headcount, expanding infrastructure, and supporting ongoing experiments.

## Funding rounds

- Seed, Oct 9, 2023, $9.3M — Horizons Ventures, Octopus Investments, Air Street Capital, Verve Ventures

## Investors

- Horizons Ventures — Seed
- Octopus Investments (https://capitalatlas.ai/funds/octopus-investments) — Seed
- Air Street Capital (https://capitalatlas.ai/funds/air-street-capital) — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed